Study guide
6.1 Sickle Cell Disease
Certified Pediatric Hematology Oncology Nurse CPHON®
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy
2 Care Continuum
2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship
3 Leukemias and Lymphomas
3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas
4 CNS, Neuroblastoma, and Renal Tumors
4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors
5 Sarcomas and Other Solid Tumors
5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors
6 Hematologic Disorders
6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure
7 Pathophysiology, Genetics, and Diagnostics
7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis
8 Clinical Trials and Professional Performance
8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education
9 Chemotherapy and Biotherapy
9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy
10 Immunotherapy, Cellular Therapy, and Radiation
10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam
11 HSCT, Surgery, Transfusion, and Coagulation Therapy
11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy
12 Neurologic, Respiratory, and Cardiovascular Effects
12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects
13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects
13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects
14 Endocrine, Hematologic, Immunologic, and Sensory Effects
14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects
15 Pain, Sleep, Fatigue, and Mental Health
15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects
16 Supportive Care
16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care
17 Infectious and Gastrointestinal Emergencies
17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction
18 Metabolic Emergencies
18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome
19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome
19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)
20 Sickle Cell and Hemostasis Emergencies
20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed
21 Cardiopulmonary Emergencies
21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias
22 Neurologic and Infusion Emergencies
22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation
23 Family, Caregivers, and Social Integration
23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment
24 Development, Grief, Culture, and Community Resources
24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources
6.1 Sickle Cell Disease
Key Takeaways Explain This Topic AI
HbSS and HbS–β0-thalassemia are typically the most severe genotypes; HbSC and HbS–β+ are often milder but still cause vaso-occlusion, acute chest syndrome, and organ injury.
Newborn screening identifies hemoglobin S before symptoms; confirmatory electrophoresis or HPLC distinguishes disease from trait and separates SS, SC, and S–β-thalassemia.
Deoxygenated HbS polymerizes, driving vaso-occlusion, hemolysis, and endothelial inflammation; functional asplenia makes fever an emergency.
Prevention includes penicillin prophylaxis, pneumococcal vaccination, hydroxyurea (raises HbF; monitor the CBC), transcranial Doppler stroke screening in HbSS, and transfusion or exchange for stroke, severe acute chest syndrome, and severe anemia, with iron-overload surveillance.
Vaso-occlusive pain uses age-appropriate opioids; meperidine is avoided because of seizures. VOC, acute chest syndrome, and sequestration are signposted to later emergency chapters.
Last updated: August 2026
Sickle cell disease (SCD) is not one diagnosis. It is a family of β-globin disorders in which hemoglobin S (HbS) polymerizes when deoxygenated, distorting red cells into the sickle shape that gives the disease its name. CPHON items test whether you can place a child on the genotype map, explain the linked loops of polymerization, vaso-occlusion, hemolysis, and endothelial inflammation, and run the prevention program that keeps children out of the emergency department. Acute vaso-occlusive crisis (VOC), acute chest syndrome (ACS), and splenic sequestration are named pediatric hematology emergencies later in this guide. This section is the disease framework: newborn identification, prophylaxis, hydroxyurea, transfusion strategy, stroke screening, and the few acute scripts—fever, parvovirus aplastic crisis, and priapism—you must not miss at a clinic visit.
Genotypes: HbSS, HbSC, and HbS–β-thalassemia
HbSS (homozygous sickle cell anemia) is the most common severe genotype. Both β-globin alleles carry the sickle mutation, so after fetal hemoglobin (HbF) declines in infancy there is essentially no hemoglobin A (HbA). Children develop chronic hemolytic anemia, dactylitis, functional asplenia, and a high rate of VOC, ACS, and ischemic stroke if they are not on a prevention plan.
HbSC disease is compound heterozygous for HbS and hemoglobin C. Steady-state hemoglobin is often higher and hemolysis milder than in HbSS, but vaso-occlusion still occurs. Families hear “milder” and delay fever care; that is a nursing failure. HbSC is also associated with avascular necrosis and proliferative retinopathy, so organ surveillance still belongs on the calendar.
HbS–β-thalassemia splits by residual β-globin production. HbS–β0-thalassemia makes no normal β-globin from the thalassemia allele and behaves like HbSS. HbS–β+-thalassemia retains some HbA and is often closer to HbSC in severity. A 9-year-old listed only as “sickle-beta thal” is incompletely labeled until you know β0 versus β+. Trait (HbAS) is not SCD; carriers are generally asymptomatic for vaso-occlusion and need counseling, not penicillin.
- Genotype Residual HbA Typical intensity TCD stroke-screening emphasis
- HbSS None Severe hemolysis and vaso-occlusion Highest-yield group
- HbS–β0-thalassemia None Similar to HbSS Treat like HbSS
- HbSC None (S + C) Often milder hemolysis; still VOC, ACS, retinopathy Individualize with hematology
- HbS–β+-thalassemia Some HbA Often milder Individualize with hematology
- Newborn screening before the first symptom
Universal newborn screening detects HbS before dactylitis or pneumococcal sepsis. Methods vary by state (HPLC, isoelectric focusing, or related assays). The screen is not the final genotype. Confirmatory hemoglobin electrophoresis or HPLC, with parental studies or DNA when needed, distinguishes SS, SC, S–β-thalassemia, and trait. An FS pattern (fetal plus sickle, no A) in a neonate is presumed HbSS or S–β0 until confirmatory testing. Penicillin should not wait for a perfect genotype letter if SCD is likely.
Teach that the infant looks well because of residual HbF. The first teaching visit is fever response, spleen palpation for sequestration teaching, and prophylaxis—not waiting for a pain crisis to “prove” the diagnosis. A 6-week-old whose screen showed FS and whose confirmatory HPLC is still pending should already be on penicillin and have a written fever number.
Pathophysiology: three linked loops
Deoxygenation, acidosis, dehydration, cold, and stasis promote HbS polymerization . Rigid cells obstruct microvasculature ( vaso-occlusion ). Repeated membrane injury shortens red-cell survival ( hemolysis ). Free plasma hemoglobin scavenges nitric oxide; endothelium activates; leukocytes and platelets adhere; a chronic inflammatory vasculopathy develops. SCD is therefore ischemia plus hemolysis plus endothelial injury, not “just a low hemoglobin.”
The spleen infarcts in early childhood in HbSS, producing functional asplenia . Encapsulated organisms, especially Streptococcus pneumoniae , become life-threatening. That single anatomic fact drives penicillin, pneumococcal vaccination, and the rule that fever is an emergency .
Prevention backbone
Penicillin prophylaxis starts in infancy after SCD is identified or strongly suspected on the newborn screen and is typically continued at least through early childhood—commonly until about age 5 years in HbSS and similarly severe genotypes—per hematology protocol. Your job is adherence, liquid-to-tablet transitions, and not improvising a stop date because the child “looks well.”
Pneumococcal vaccination uses the pediatric conjugate series (PCV) plus polysaccharide vaccine (PPSV23) on the asplenia schedule, along with influenza and meningococcal vaccines as indicated. Vaccines do not replace penicillin; penicillin does not replace vaccines.
Hydroxyurea increases HbF, which interferes with HbS polymerization. It reduces VOC, ACS, and transfusion need and is offered broadly in children, including young children, on contemporary guidelines. Nursing monitoring is a CBC (often with reticulocyte count) because myelosuppression is dose-limiting. Hold or adjust per protocol for neutropenia, thrombocytopenia, or reticulocytopenia. Teach that hydroxyurea is not a daily pain pill; benefit requires consistent dosing and laboratory follow-up. A 4-year-old with HbSS whose parent stops hydroxyurea after one pain-free month needs restart counseling and a scheduled CBC, not scolding without a plan.
Transfusion and exchange. Simple transfusion treats symptomatic severe anemia—aplastic crisis, severe sequestration after initial volume resuscitation, or an abrupt drop from baseline. Exchange transfusion raises HbA and lowers the HbS fraction without overshooting viscosity; classic indications include overt ischemic stroke and severe ACS . Chronic transfusion programs prevent recurrent stroke and treat children with abnormal transcranial Doppler (TCD) velocities. Iron accumulation is the long-term cost: ferritin trends plus MRI T2* of liver and heart, then chelation (chelator toxicities are taught with thalassemia in the next section).
Stroke screening. In HbSS and similarly severe S–β0 disease, TCD from early childhood identifies elevated cerebral arterial velocities that predict ischemic stroke. An abnormal TCD leads to a chronic transfusion discussion, not a “see you next year.” This is primary prevention, distinct from the emergency chapter on acute stroke.
Clinic scripts that are not the full emergency chapters
VOC is ischemic pain. Use age-appropriate opioids (morphine, hydromorphone, fentanyl as indicated), hydration, and incentive spirometry to reduce ACS. Avoid meperidine ; its metabolite normeperidine lowers the seizure threshold—a historically documented problem in SCD. NSAIDs may be adjuncts when kidneys and gastritis risk allow; they do not replace opioids for severe VOC. Detailed PCA titration and ACS respiratory support belong in later emergency sections.
Fever in SCD is an emergency because of functional asplenia. A 3-year-old with HbSS and 38.5°C does not wait for morning clinic. Blood culture, prompt parenteral antibiotics covering pneumococcus, and a CBC with reticulocyte count are the opening moves.
Aplastic crisis from parvovirus B19 arrests erythropoiesis. Short-lived SCD red cells make hemoglobin crash while reticulocytes disappear. Transfuse as needed; flag pregnant staff for exposure counseling. This is not sequestration: the spleen is not rapidly enlarging, and the reticulocyte count is low, not high.
Priapism is corporal vaso-occlusion. Time the event, give analgesia and hydration, involve hematology and urology, and teach boys and parents to report an erection lasting hours. Prolonged ischemia risks impotence.
ACS (new infiltrate plus respiratory symptoms or fever) and acute splenic sequestration (rapidly enlarging spleen, falling hemoglobin, high reticulocytes in a young child who still has a spleen) are signposted here so you recognize them as SCD complications. Their step-by-step emergency management is not duplicated in this chapter.
The CPHON product is a family that knows the genotype, gives penicillin, keeps vaccines current, understands hydroxyurea and CBC checks, treats fever as an emergency, and has a TCD and transfusion plan when the genotype demands it.